Chemokine receptor antagonist and cyclosporin in combined therapy
View Patent ↗The use of a chemokine receptor antagonist together with a cyclosporin to produce a pharmaceutical composition for treating or preventing rejection of transplanted organs, tissues or cells is herein disclosed. Said pharmaceutical compositions for the simultaneous, sepatate or sequential use of its active ingredients for the above specified therapy are also disclosed and claimed. In particular, the use of Met-RANTES together with cyclosporin A to produce a pharmaceutical composition for the treatment of renal allograft transplant rejection is experimentally shown.
1. A method of treating or preventing the rejection of transplanted organs, tissues or cells which comprises administering to a subject in need thereof (1) a chemokine receptor antagonist for the RANTES receptors said antagonist selected from the group consisting of Met-RANTES, Leu-RANTES, Gln-RANTES, amino terminally truncated RANTES missing the first two amino acid residues, amino terminally truncated RANTES missing the first five amino acid residues, amino terminally truncated RANTES missing the first six amino acid residues, amino terminally truncated RANTES missing the first seven amino acid residues, amino terminally truncated RANTES missing the first eight amino acid residues, and amino terminally truncated RANTES missing the first nine amino acid residues and (2) a cyclosporin to treat or prevent the rejection of transplanted organs, tissues or cells.
2. The method according to claim 1 , wherein the rejection treated or prevented is renal allograft transplantation rejection.
3. The method according to claim 1 , wherein the chemokine receptor antagonist and cyclosporin are administered simultaneously.
4. The method according to claim 1 , wherein the chemokine receptor antagonist and cyclosporin are administered sequentially or separately.
5. The method according to claim 1 , wherein the chemokine receptor antagonist is Gln-RANTES.
6. The method according to claim 1 , wherein the chemokine receptor antagonist is Leu-RANTES.
7. The method according to claim 1 , wherein the chemokine receptor antagonist is Met-RANTES.
8. The method according to claim 1 , wherein the cyclosporin is cyclosporin A.
9. The method according to claim 8 , wherein the chemokine receptor antagonist is Met-RANTES.
10. The method according to claim 9 , wherein the rejection treated or prevented is renal allograft transplantation rejection.
11. A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and the combination of (1) a chemokine receptor antagonist for the RANTES receptors said antagonist selected from the group consisting of Met-RANTES, Leu-RANTES, Gln-RANTES, amino terminally truncated RANTES missing the first two amino acid residues, amino terminally truncated RANTES missing the first five amino acid residues, amino terminally truncated RANTES missing the first six amino acid residues, amino terminally truncated RANTES missing the first seven amino acid residues, amino terminally truncated RANTES missing the first eight amino acid residues, and amino acid residues terminally truncated RANTES missing the first nine and (2) a cyclosporin.
12. The pharmaceutical composition according to claim 11 , wherein the chemokine receptor antagonist is Gln-RANTES.
13. The pharmaceutical composition according to claim 11 , wherein the chemokine receptor antagonist is Leu-RANTES.
14. The pharmaceutical according to claim 11 , wherein the chemokine receptor antagonist is Met-RANTES.
15. The pharmaceutical composition according to claim 11 , wherein the cyclosporin is cyclosporin A.
16. The pharmaceutical composition according to claim 15 , wherein the chemokine receptor antagonist is Met-RANTES.